Therapeutic applicability of anti-inflammatory and proresolving polyunsaturated fatty acid-derived lipid mediators

TheScientificWorldJournal

Volumn 10, Issue , 2010, Pages 676-712

  Bannenberg, Gerard L ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Anti inflammatory; Apoptosis; Aspirin; Inflammation; Leukocyte; Lipid mediator; Protectins; Resolution; Resolvins

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CD59 ANTIGEN; CYCLOPENTENONE; DOCOSAHEXAENOIC ACID; FLUPROSTENOL; ICOSAPENTAENOIC ACID; LATANOPROST; LIPOXIN A; LIPOXIN B; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; RESOLVIN; UNCLASSIFIED DRUG; ZK 994;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CYTOKINE RELEASE; GLAUCOMA; HUMAN; INFLAMMATION; LIPID METABOLISM; LIPOGENESIS; NEUROTRANSMISSION; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; FATTY ACIDS; HUMANS; INFLAMMATION MEDIATORS; LIPID METABOLISM;

EID: 77952897873     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2010.57     Document Type: Review

References (315)

1. Cotran, R.S., Kumar, V., and Collins, T. (1999) Robbins Pathologic Basis of Disease. W.B. Saunders, Philadelphia.
2. Majno, G. and Joris, I. (1996) Cells, Tissues, and Disease. Principles of General Pathology. Blackwell Science, Cambridge, MA.
3. Plytycz, B. and Seljelid, R. (2003) From inflammation to sickness: historical perspective. Arch. Immunol. Ther. Exp. (Warsz) 51, 105-109.
4. Berczi, I., Quintanar-Stephano, A., and Kovacs, K. (2009) Neuroimmune regulation in immunocompetence, acute illness, and healing. Ann. N. Y. Acad. Sci. 1153, 220-239.
5. Pecchi, E., Dallaporta, M., Jean, A., Thirion, S., and Troadec, J.D. (2009) Prostaglandins and sickness behavior: old story, new insights. Physiol. Behav. 97, 279-292.
6. Medzhitov, R. and Janeway, C.J. (2000) Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173, 89-97. (Pubitemid 30095213)
7. Nathan, C. (2006) Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 6, 173-182.
8. Iwasaki, A. and Medzhitov, R. (2010) Regulation of adaptive immunity by the innate immune system. Science 327, 291-295.
9. Kolaczkowska, E. (2002) Shedding light on vascular permeability during peritonitis: role of mast cell histamine versus macrophage cysteinyl leukotrienes. Inflamm. Res. 51, 519-521.
10. Metchnikoff, E. (1893) Lectures on Comparative Pathology of Inflammation. New York.
11. Serhan, C.N. and Savill, J. (2005) Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6, 1191-1197.
12. Bannenberg, G., Arita, M., and Serhan, C.N. (2007) Endogenous receptor agonists: resolving inflammation. TheScientificWorldJOURNAL 7, 1440-1462. (Pubitemid 47439737)
13. Fabry, Z., Schreiber, H.A., Harris, M.G., and Sandor, M. (2008) Sensing the microenvironment of the central nervous system: immune cells in the central nervous system and their pharmacological manipulation. Curr. Opin. Pharmacol. 8, 496-507.
14. Gronert, K. (2008) Lipid autacoids in inflammation and injury responses: a matter of privilege. Mol. Interv. 8, 28-35.
15. Nathan, C. (2002) Points of control in inflammation. Nature 420, 846-852.
16. Serhan, C.N., Brain, S.D., Buckley, C.D., Gilroy, D.W., Haslett, C., O'Neill, L.A., Perretti, M., Rossi, A.G., and Wallace, J.L. (2007) Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21, 325-332. (Pubitemid 46213480)
17. Hao, S. and Baltimore, D. (2009) The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nat. Immunol. 10, 281-288.
18. Haslett, C. (1992) Resolution of acute inflammation and the role of apoptosis in the tissue fate of granulocytes. Clin. Sci. (Lond.) 83, 639-648.
19. Kolaczkowska, E., Koziol, A., Plytycz, B., and Arnold, B. (2009) Inflammatory macrophages, and not only neutrophils, die by apoptosis during acute peritonitis. Immunobiology. [Epub ahead of print]
20. Campbell, E.L., Louis, N.A., Tomassetti, S.E., Canny, G.O., Arita, M., Serhan, C.N., and Colgan, S.P. (2007) Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J. 21, 3162-3170. (Pubitemid 47565535)
21. Godson, C., Mitchell, S., Harvey, K., Petasis, N.A., Hogg, N., and Brady, H.R. (2000) Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164, 1663-1667. (Pubitemid 30108713)
22. Freire-de-Lima, C.G., Xiao, Y.Q., Gardai, S.J., Bratton, D.L., Schiemann, W.P., and Henson, P.M. (2006) Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J. Biol. Chem. 281, 38376-38384.
23. Huynh, M.L., Fadok, V.A., and Henson, P.M. (2002) Phosphatidylserine- dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J. Clin. Invest. 109, 41-50.
24. Fadok, V.A., Bratton, D.L., Konowal, A., Freed, P.W., Westcott, J.Y., and Henson, P.M. (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Invest. 101, 890-898. (Pubitemid 28096086)
25. Willoughby, D.A., Moore, A.R., Colville-Nash, P.R., and Gilroy, D. (2000) Resolution of inflammation. Int. J. Immunopharmacol. 22, 1131-1135.
26. Serhan, C.N., Yacoubian, S., and Yang, R. (2008) Anti-inflammatory and proresolving lipid mediators. Annu. Rev. Pathol. 3, 279-312.
27. Serhan, C.N. (2006) Resolution phases of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25, 101-137.
28. Cronstein, B.N., Levin, R.I., Philips, M., Hirschhorn, R., Abramson, S.B., and Weissmann, G. (1992) Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J. Immunol. 148, 2201-2206.
29. Zanardo, R.C., Brancaleone, V., Distrutti, E., Fiorucci, S., Cirino, G., and Wallace, J.L. (2006) Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J. 20, 2118-2120. (Pubitemid 44953872)
30. Li, L., Hsu, A., and Moore, P. (2009) Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation - a tale of three gases! Pharmacol. Ther. 123, 386-400.
31. Barnes, P.J. and Adcock, I. (1993) Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol. Sci. 14, 436-441.
32. Uller, L., Persson, C.G., and Erjefalt, J.S. (2006) Resolution of airway disease: removal of inflammatory cells through apoptosis, egression or both? Trends Pharmacol. Sci. 27, 461-466. (Pubitemid 44251226)
33. Ariel, A., Fredman, G., Sun, Y.P., Kantarci, A., Van Dyke, T.E., Luster, A.D., and Serhan, C.N. (2006) Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat. Immunol. 7, 1209-1216. (Pubitemid 44594317)
34. Weissmann, G., Serhan, C., Korchak, H.M., and Smolen, J.E. (1982) Neutrophils: release of mediators of inflammation with special reference to rheumatoid arthritis. Ann. N. Y. Acad. Sci. 389, 11-24. (Pubitemid 12013174)
35. Nimmo, A.J. and Vink, R. (2009) Recent patents in CNS drug discovery: the management of inflammation in the central nervous system. Recent Pat. CNS Drug Discov. 4, 86-95.
36. Hansson, G., Robertson, A.K.L., and Soderberg-Naucler, C. (2006) Inflammation and atherosclerosis. Annu. Rev. Pathol. Mech. Dis. 1, 297-329.
37. Van Dyke, T.E. and Serhan, C.N. (2003) Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J. Dent. Res. 82, 82-90.
38. Sewell, G.W., Marks, D.J., and Segal, A.W. (2009) The immunopathogenesis of Crohn's disease: a three-stage model. Curr. Opin. Immunol. 21, 506-513.
39. Wallace, J.M. (2002) Nutritional and botanical modulation of the inflammatory cascade-eicosanoids, cyclooxygenases, and lipoxygenases-as an adjunct in cancer therapy. Integr. Cancer Ther. 1, 7-37.
40. Eikelenboom, P., Veerhuis, R., Scheper, W., Rozemuller, A.J., van Gool, W.A., and Hoozemans, J.J. (2006) The significance of neuroinflammation in understanding Alzheimer's disease. J. Neural Transm. 113, 1685-1695. (Pubitemid 44657664)
41. Wills-Karp, M. (2007) Complement activation pathways: a bridge between innate and adaptive immune responses in asthma. Proc. Am. Thorac. Soc. 4, 247-251.
42. Krishnamoorthy, S. and Honn, K.V. (2008) Eicosanoids in tumor progression and metastasis. Subcell. Biochem. 49, 145-168.
43. Calder, P.C. (2006) n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 83, 1505S-1519S.
44. Sugita, S. (2009) Role of ocular pigment epithelial cells in immune privilege. Arch. Immunol. Ther. Exp. (Warsz) 57, 263-268.
45. Goldmann, B.U., Rudolph, V., Rudolph, T.K., Holle, A.K., Hillebrandt, M., Meinertz, T., and Baldus, S. (2009) Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction. Free Radic. Biol. Med. 47, 79-83.
46. Dallegri, F. and Ottonello, L. (1997) Tissue injury in neutrophilic inflammation. Inflamm. Res. 46, 382-391.
47. Weiss, S.J. (1989) Tissue destruction by neutrophils. N. Engl. J. Med. 320, 365-376.
48. Ward, P.A. (1991) Mechanisms of endothelial cell killing by H2O2 or products of activated neutrophils. Am. J. Med. 91, 89S-94S.
49. Pullar, J.M., Vissers, M.C., and Winterbourn, C.C. (2000) Living with a killer: the effects of hypochlorous acid on mammalian cells. IUBMB Life 50, 259-266.
50. Tsukamoto, T., Chanthaphavong, R.S., and Pape, H.C. (2009) Current theories on the pathophysiology of multiple organ failure after trauma. Injury 41(1), 21-26.
51. Medzhitov, R. (2008) Origin and physiological roles of inflammation. Nature 454, 428-435.
52. Rainsford, K.D. (2007) Anti-inflammatory drugs in the 21st century. Subcell. Biochem. 42, 3-27.
53. Matthay, M.A., Uchida, T., and Fang, X. (2002) Clinical acute lung injury and acute respiratory distress syndrome. Curr. Treat. Options Cardiovasc. Med. 4, 139-149.
54. Lawrence, T. and Gilroy, D.W. (2007) Chronic inflammation: a failure of resolution? Int. J. Exp. Pathol. 88, 85-94. (Pubitemid 46570075)
55. 4 up-regulate transcriptional corepressor NAB1 in human neutrophils. FASEB J. 15, 2736-2738.
56. Maderna, P., Godson, C., Hannify, G., Murphy, M., and Brady, H.R. (2000) Influence of lipoxin A(4) and other lipoxygenase-derived eicosanoids on tissue factor expression. Am. J. Physiol. Cell. Physiol. 279, C945-953.
57. Kieran, N.E., Doran, P.P., Connolly, S.B., Greenan, M.C., Higgins, D.F., Leonard, M., Godson, C., Taylor, C.T., Henger, A., Kretzler, M., Burne, M.J., Rabb, H., and Brady, H.R. (2003) Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog. Kidney Int. 64, 480-492.
58. Hansson, A., Serhan, C.N., Haeggstrom, J., Ingelman-Sundberg, M., and Samuelsson, B. (1986) Activation of protein kinase C by lipoxin A and other eicosanoids. Intracellular action of oxygenation products of arachidonic acid. Biochem. Biophys. Res. Commun. 134, 1215-1222.
59. Katoh, T., Takahashi, K., DeBoer, D.K., Serhan, C.N., and Badr, K.F. (1992) Renal hemodynamic actions of lipoxins in rats: a comparative physiological study. Am. J. Physiol. 263, F436-442.
60. Dahlén, S.E., Raud, J., Serhan, C.N., Björk, J., and Samuelsson, B. (1987) Biological activities of lipoxin A include lung strip contraction and dilation of arterioles in vivo. Acta Physiol. Scand. 130, 643-647.
61. Svensson, C.I., Zattoni, M., and Serhan, C.N. (2007) Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing. J. Exp. Med. 204, 245-252.
62. Tamaoki, J., Tagaya, E., Yamawaki, I., and Konno, K. (1995) Lipoxin A4 inhibits cholinergic neurotransmission through nitric oxide generation in the rabbit trachea. Eur. J. Pharmacol. 287, 233-238.
63. Sri Kantha, S., Matsumura, H., Kubo, E., Kawase, K., Takahata, R., Serhan, C.N., and Hayaishi, O. (1994) Effects of prostaglandin D2, lipoxins and leukotrienes on sleep and brain temperature of rats. Prostaglandins Leukot. Essent. Fatty Acids 51, 87-93.
64. Serhan, C.N. (2009) Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. J. Thromb. Haemost. Suppl. 1, 44-48.
65. 4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int. 47, 1295-1302.
66. Serhan, C.N., Hamberg, M., and Samuelsson, B. (1984) Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes. Biochem. Biophys. Res. Commun. 118, 943-949. (Pubitemid 14194804)
67. 4. Adv. Prostaglandin Thromboxane Leukot. Res. 20, 54-62.
68. 4. Impact of aspirin therapy. Circulation 86, 56-63.
69. Levy, B.D., Bonnans, C., Silverman, E.S., Palmer, L.J., Marigowda, G., Israel, E., and Severe Asthma Research Program, National Heart, Lung, and Blood Institute (2005) Diminished lipoxin biosynthesis in severe asthma. Am. J. Respir. Crit. Care Med. 172, 824-830.
70. 4 and related compounds: development of new extraction techniques for lipoxins. Lab. Invest. 82, 1253-1254.
71. 4 and N-formyl-L-methionyl-Lleucyl-L-phenylalanine. Clin. Sci. (Lond.) 77, 195-203.
72. Colgan, S.P. (2002) Lipid mediators in epithelial cell-cell interactions. Cell. Mol. Life Sci. 59, 754-760.
73. 4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J. Immunol. 156, 2264-2272.
74. 4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J. Exp. Med. 189, 1923-1930.
75. 4. Pediatr. Res. 64, 393-398.
76. 4, and their analogs selectively downregulate PMN azurophilic degranulation. Am. J. Physiol. 276, C988-994.
77. Gewirtz, A.T., McCormick, B., Neish, A.S., Petasis, N.A., Gronert, K., Serhan, C.N., and Madara, J.L. (1998) Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogs. J. Clin. Invest. 101, 1860-1869. (Pubitemid 28226104)
78. 4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J. Exp. Med. 183, 137-146.
79. Filep, J.G. and Kebir, D.E. (2009) Neutrophil apoptosis: a target for enhancing the resolution of inflammation. J. Cell. Biochem. 108, 1039-1046.
80. Serhan, C.N. and Chiang, N. (2002) Lipid-derived mediators in endogenous anti-inflammation and resolution: lipoxins and aspirin-triggered 15-epi-lipoxins. TheScientificWorldJOURNAL 2, 169-204.
81. 4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells. Am. J. Physiol. Cell Physiol. 296, C1420-C1147.
82. Fiore, S., Maddox, J.F., Perez, H.D., and Serhan, C.N. (1994) Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J. Exp. Med. 180, 253-260. (Pubitemid 24181074)
83. Serhan, C.N., Hamberg, M., Samuelsson, B., Morris, J., and Wishka, D.G. (1986) On the stereochemistry and biosynthesis of lipoxin B. Proc. Natl. Acad. Sci. U. S. A. 83, 1983-1987.
84. 2+ mobilization with leukotriene A4 and epoxytetraenes in human neutrophils. Biochem. Pharmacol. 39, 355-365.
85. 4: evidence for differential Ca2+ mobilization. J. Immunol. 157, 2149-2154.
86. Samuelsson, B. (1987) An elucidation of the arachidonic acid cascade. Discovery of prostaglandins, thromboxane and leukotrienes. Drugs 33, 2-9. (Pubitemid 17070100)
87. Ferreira, S.H. (2002) Peripheral analgesic sites of action of anti-inflammatory drugs. Int. J. Clin. Pract. Suppl. 128, 2-10. (Pubitemid 34839472)
88. Samuelsson, B., Morgenstern, R., and Jakobsson, P.J. (2007) Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev. 59, 207-224. (Pubitemid 47481434)
89. Samuelsson, B., Goldyne, M., Granström, E., Hamberg, M., Hammarström, S., and Malmsten, C. (1978) Prostaglandins and thromboxanes. Annu. Rev. Biochem. 47, 997-1029.
90. Kuehl, F.A.J. and Egan, R.W. (1980) Prostaglandins, arachidonic acid, and inflammation. Science 210, 978-984.
91. Morley, J. (1978) Prostaglandins and lymphokines in inflammation. Rheumatol. Rehabil. Suppl., 18-24.
92. Kapoor, M., Kojima, F., Yang, L., and Crofford, L.J. (2007) Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot. Essent. Fatty Acids 76, 103-112. (Pubitemid 46217229)
93. 2 at new glance: novel insights in functional diversity offer therapeutic chances. Int. J. Biochem. Cell Biol. 42(2), 198-201.
94. Raud, J., Dahlén, S.E., Sydbom, A., Lindbom, L., and Hedqvist, P. (1988) Enhancement of acute allergic inflammation by indomethacin is reversed by prostaglandin E2: apparent correlation with in vivo modulation of mediator release. Proc. Natl. Acad. Sci. U. S. A. 85, 2315-2319. (Pubitemid 24315882)
95. 4 hydrolase but do not express 5-lipoxygenase activity. Prostaglandins Leukot. Essent. Fatty Acids 51, 263-270.
96. Scher, J.U. and Pillinger, M.H. (2009) The anti-inflammatory effects of prostaglandins. J. Investig. Med. 57, 703-708.
97. St-Onge, M., Dumas, A., Michaud, A., Laflamme, C., Dussault, A.A., and Pouliot, M. (2009) Impact of anti-inflammatory agents on the gene expression profile of stimulated human neutrophils: unraveling endogenous resolution pathways. PLoS One 4, e4902.
98. Gomez, P.F., Pillinger, M.H., Attur, M., Marjanovic, N., Dave, M., Park, J., Bingham, C.O., 3rd, Al-Mussawir, H., and Abramson, S.B. (2005) Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-kB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts. J. Immunol. 175, 6924-6930.
99. Narumiya, S. (2009) Prostanoids and inflammation: a new concept arising from receptor knockout mice. J. Mol. Med. 87, 1015-1022.
100. Zurier, R.B., Hoffstein, S., and Weissmann, G. (1973) Suppression of acute and chronic inflammation in adrenalectomized rats by pharmacologic amounts of prostaglandins. Arthritis Rheum. 16, 606-618.
101. Coll, T., Palomer, X., Blanco-Vaca, F., Escolà-Gil, J.C., Sánchez, R.M., Laguna, J.C., and Vázquez-Carrera, M. (2009) Cyclooxygenase 2 inhibition exacerbates palmitate-induced inflammation and insulin resistance in skeletal muscle cells. Endocrinology 151(2), 537-548.
102. Vancheri, C., Mastruzzo, C., Sortino, M.A., and Crimi, N. (2004) The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol. 25, 40-46.
103. 2. J. Inflamm. (Lond.) 6, 30.
104. Kabashima, K., Saji, T., Murata, T., Nagamachi, M., Matsuoka, T., Segi, E., Tsuboi, K., Sugimoto, Y., Kobayashi, T., Miyachi, Y., Ichikawa, A., and Narumiya, S. (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 109, 883-893.
105. Bandeira-Melo, C., Serra, M.F., Diaz, B.L., Cordeiro, R.S., Silva, P.M., Lenzi, H.L., Bakhle, Y.S., Serhan, C.N., and Martins, M.A. (2000) Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia. J. Immunol. 164, 1029-1036.
106. Aspinall, R.L. and Cammarata, P.S. (1969) Effect of prostaglandin E2 on adjuvant arthritis. Nature 224, 1320-1321.
107. Masferrer, J.L., Zweifel, B.S., Manning, P.T., Hauser, S.D., Leahy, K.M., Smith, W.G., Isakson, P.C., and Seibert, K. (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. U. S. A. 91, 3228-3232.
108. Levy, B.D., Clish, C.B., Schmidt, B., Gronert, K., and Serhan, C.N. (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2, 612-619.
109. Ajuebor, M.N., Singh, A., and Wallace, J.L. (2000) Cyclooxygenase-2- derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G238-244.
110. Murakami, Y., Akahoshi, T., Hayashi, I., Endo, H., Hashimoto, A., Kono, S., Kondo, H., Kawai, S., Inoue, M., and Kitasato, H. (2003) Inhibition of monosodium urate monohydrate crystal-induced acute inflammation by retrovirally transfected prostaglandin D synthase. Arthritis Rheum. 48, 2931-2941.
111. Bannenberg*, G.L., Chiang*, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K.H., Hong, S., and Serhan, C.N. (2005) Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174, 4345-4355. *Shared first authors.
112. Schuligoi, R., Grill, M., Heinemann, A., Peskar, B.A., and Amann, R. (2005) Sequential induction of prostaglandin E and D synthases in inflammation. Biochem. Biophys. Res. Commun. 335, 684-689.
113. Gilroy, D.W., Colville-Nash, P.R., Willis, D., Chivers, J., Paul-Clark, M.J., and Willoughby, D.A. (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5, 698-701.
114. 2. Proc. Natl. Acad. Sci. U. S. A. 104, 20979-20984.
115. Jiang, C., Ting, A.T., and Seed, B. (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86.
116. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., and Glass, C.K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82.
117. Lawrence, T., Willoughby, D.A., and Gilroy, D.W. (2002) Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. Immunol. 2, 787-795. (Pubitemid 37328718)
118. 2 attenuates the development of acute and chronic inflammation. Mol. Pharmacol. 61, 997-1007.
119. Kim, E.H. and Surh, Y.J. (2006) 15-Deoxy-Delta(12,14)-prostaglandin J(2) as a potential endogenous regulator of redox-sensitive transcription factors. Biochem. Pharmacol. 72, 1516-1528.
120. Oliva, J.L., Perez-Sala, D., Castrillo, A., Martinez, N., Canada, F.J., Bosca, L., and Rojas, J.M. (2003) The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and activates H-Ras. Proc. Natl. Acad. Sci. U. S. A. 100, 4772-4777.
121. Renedo, M., Gayarre, J., Garcia-Dominguez, C., Perez-Rodriguez, A., Prieto, A., Cañada, F., Rojas, J., and Perez-Sala, D. (2007) Modification and activation of Ras proteins by electrophilic prostanoids with different structure are site-selective. Biochemistry 47, 6607-6616. (Pubitemid 46870126)
122. Mochizuki, M., Ishii, Y., Itoh, K., Iizuka, T., Morishima, Y., Kimura, T., Kiwamoto, T., Matsuno, Y., Hegab, A.E., Nomura, A., Sakamoto, T., Uchida, K., Yamamoto, M., and Sekizawa, K. (2005) Role of 15-deoxy delta(12,14) prostaglandin J2 and Nrf2 pathways in protection against acute lung injury. Am. J. Respir. Crit. Care Med. 171, 1260-1266. (Pubitemid 40740733)
123. Ianaro, A., Ialenti, A., Maffia, P., Pisano, B., and Di Rosa, M. (2001) HSF1/hsp72 pathway as an endogenous anti-inflammatory system. FEBS Lett. 499, 239-244. (Pubitemid 32553872)
124. Trivedi, S.G., Newson, J., Rajakariar, R., Jacques, T.S., Hannon, R., Kanaoka, Y., Eguchi, N., Colville-Nash, P., and Gilroy, D.W. (2006) Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. Proc. Natl. Acad. Sci. U. S. A. 103, 5179-5184.
125. Ward, C., Dransfield, I., Murray, J., Farrow, S.N., Haslett, C., and Rossi, A.G. (2002) Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-activated receptor-gamma-independent mechanism. J. Immunol. 168, 6232-6243. (Pubitemid 34620043)
126. Lawrence, T., Gilroy, D.W., Colville-Nash, P.R., and Willoughby, D.A. (2001) Possible new role for NF-kappaB in the resolution of inflammation. Nat. Med. 7, 1291-1297. (Pubitemid 34007932)
127. Hortelano, S., Castrillo, A., Alvarez, A.M., and Boscá, L. (2000) Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages. J. Immunol. 165, 6525-6531.
128. Straus, D.S. and Glass, C.K. (2001) Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med. Res. Rev. 21, 185-210.
129. Morrow, J.D. (2006) The isoprostanes - unique products of arachidonate peroxidation: their role as mediators of oxidant stress. Curr. Pharm. Des. 12, 895-902.
130. Pierre, S.R., Lemmens, M.A., and Figueiredo-Pereira, M.E. (2009) Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice. J. Neuroinflammation 6, 18.
131. Bureau, F., Desmet, C., Mélotte, D., Jaspar, F., Volanti, C., Vanderplasschen, A., Pastoret, P., Piette, J., and Lekeux, P. (2002) A proinflammatory role for the cyclopentenone prostaglandins at low micromolar concentrations: oxidative stress-induced extracellular signal-regulated kinase activation without NF-kappa B inhibition. J. Immunol. 168, 5318-5325. (Pubitemid 34496000)
132. Spite, M., Summers, L., Porter, T.F., Srivastava, S., Bhatnagar, A., and Serhan, C.N. (2009) Resolvin D1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress. Br. J. Pharmacol. 158(4), 1062-1073.
133. Shertzer, H.G., Bannenberg, G.L., Rundgren, M., and Moldeus, P. (1991) Relationship of membrane fluidity, chemoprotection, and the intrinsic toxicity of butylated hydroxytoluene. Biochem. Pharmacol. 42, 1587-1593.
134. Gutteridge, J.M. and Halliwell, B. (2000) Free radicals and antioxidants in the year 2000. A historical look to the future. Ann. N. Y. Acad. Sci. 899, 136-147.
135. 2. Identification of products formed in vitro. J. Biol. Chem. 258, 11713-11718.
136. 2. A prostaglandin D2 metabolite generated during inflammatory processes. J. Biol. Chem. 277, 10459-10466.
137. 2 in the presence of serum albumin. Biochim. Biophys. Acta 431, 189-193.
138. Chen, H., Chen, T., and Liu, H. (2009) Prostacyclin-induced peroxisome proliferator-activated receptor-α translocation attenuates NF-κB and TNF-α activation after renal ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol. 297, F1109-F1118.
139. Patel, N.S.A., di Paola, R., Mazzon, E., Britti, D., Thiemermann, C., and Cuzzocrea, S. (2009) Peroxisome proliferator-activated receptor-a contributes to the resolution of inflammation after renal ischemia/reperfusion injury. J. Pharmacol. Exp. Ther. 328, 635-643.
140. Falcetti, E., Flavell, D.M., Staels, B., Tinker, A., Haworth, S.G., and Clapp, L.H. (2007) IP receptor-dependent activation of PPARγ by stable prostacyclin analogues. Biochem. Biophys. Res. Commun. 360, 821-827. (Pubitemid 47077394)
141. Wilson, S.M., Shen, P., Rider, C.F., Traves, S.L., Proud, D., Newton, R., and Giembycz, M.A. (2009) Selective prostacyclin receptor agonism augments glucocorticoid-induced gene expression in human bronchial epithelial cells. J. Immunol. 183, 6788-6799.
142. Harada, N., Okajima, K., Kushimoto, S., Isobe, H., and Tanaka, K. (1999) Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 93, 157-164. (Pubitemid 29019399)
143. Eisenhut, T., Sinha, B., Gröttrup-Wolfers, E., Semmler, J., Siess, W., and Endres, S. (1993) Prostacyclin analogs suppress the synthesis of tumor necrosis factor-alpha in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology 26, 259-264. (Pubitemid 23319438)
144. Kainoh, M., Imai, R., Umetsu, T., Hattori, M., and Nishio, S. (1990) Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes. Biochem. Pharmacol. 39, 477-484. (Pubitemid 20041915)
145. Colville-Nash, P.R., Gilroy, D.W., Willis, D., Paul-Clark, M.J., Moore, A.R., and Willoughby, D.A. (2005) Prostaglandin F(2alpha) produced by inducible cyclooxygenase may contribute to the resolution of inflammation. Inflammopharmacology 12, 473-476. (Pubitemid 41607350)
146. Lecomte, M., Laneuville, O., Ji, C., DeWitt, D.L., and Smith, W.L. (1994) Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J. Biol. Chem. 269, 13207-13215. (Pubitemid 24206086)
147. Clària, J. and Serhan, C.N. (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. U. S. A. 92, 9475-9479.
148. Serhan, C.N. (2002) Endogenous chemical mediators in anti-inflammation and pro-resolution. Curr. Med. Chem. 1, 177-192.
149. 4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. U. S. A. 101, 15178-15183.
150. Morris, T., Stables, M., Hobbs, A., de Souza, P., Colville-Nash, P., Warner, T., Newson, J., Bellingan, G., and Gilroy, D.W. (2009) Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol. 183, 2089-2096.
151. Serhan, C.N., Fiore, S., Brezinski, D.A., and Lynch, S. (1993) Lipoxin A4 metabolism by differentiated HL-60 cells and human monocytes: conversion to novel 15-oxo and dihydro products. Biochemistry 32, 6313-6319. (Pubitemid 23208812)
152. Serhan, C.N. (2001) Lipoxins and aspirin-triggered 15-epi-lipoxins are endogenous components of antiinflammation: emergence of the counterregulatory side. Arch. Immunol. Ther. Exp. 49, 177-188.
153. 4 omega-hydroxylase (cytochrome P450 4F3). Arch. Biochem. Biophys. 355, 201-205.
154. 4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J. Exp. Med. 185, 1693-1704.
155. Guilford, W.J., Bauman, J.G., Skuballa, W., Bauer, S., Wei, G.P., Davey, D., Schaefer, C., Mallari, C., Terkelsen, J., Tseng, J.L., Shen, J.,
156. Serhan, C.N., Takano, T., Gronert, K., Chiang, N., and Clish, C.B. (1999) Lipoxin and aspirin-triggered 15-epilipoxin cellular interactions anti-inflammatory lipid mediators. Clin. Chem. Lab. Med. 37, 299-309. (Pubitemid 29209745)
157. Clish, C.B., Gronert, K., and Serhan, C.N. (2000) Local and systemic delivery of an aspirin-triggered lipoxin stable analog inhibits neutrophil trafficking. Ann. N. Y. Acad. Sci. 905, 274-278. (Pubitemid 30255427)
158. Maddox, J.F., Colgan, S.P., Clish, C.B., Petasis, N.A., Fokin, V.V., and Serhan, C.N. (1998) Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: design of stable lipoxin B4 analogs with increased biologic activity. FASEB J. 12, 487-494.
159. 4 in the rat heart. Prostaglandins Other Lipid Mediat. 83, 89-98.
160. 4 by pioglitazone and atorvastatin in the rat. Circulation 114, 929-935.
161. Larsen, L.N., Dahl, E., and Bremer, J. (1996) Peroxidative oxidation of leuco-dichlorofluorescein by prostaglandin H synthase in prostaglandin biosynthesis from polyunsaturated fatty acids. Biochim. Biophys. Acta 1299, 47-53. (Pubitemid 26007732)
162. 3. Prostaglandins 21, 727-738.
163. Hudert, C.A., Weylandt, K.H., Lu, Y., Wang, J., Hong, S., Dignass, A., Serhan, C.N., and Kang, J.X. (2006) Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc. Natl. Acad. Sci. U. S. A. 103, 11276-11281. (Pubitemid 44156509)
164. 5. Prostaglandins 27, 217-232.
165. 3 and icosapentaenoic acid as potential antithrombotic substances. Proc. Natl. Acad. Sci. U. S. A. 76, 5919-5923.
166. Lands, W.E. (1992) Biochemistry and physiology of n-3 fatty acids. FASEB J. 6, 2530-2536.
167. Bazan, N.G. (2007) Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr. Opin. Clin. Nutr. Metab. Care 10, 136-141. (Pubitemid 46220304)
168. Rose, D.P. and Connolly, J.M. (1999) Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol. Ther. 83, 217-244. (Pubitemid 29430123)
169. Burr, G.O. and Burr, M.M. (1929) A new deficiency disease produced by the rigid exclusion of fat from the diet. J. Biol. Chem. 82, 345-367.
170. Calder, P.C. (2009) Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 91, 791-795.
171. von Schacky, C. (2007) Omega-3 fatty acids and cardiovascular disease. Curr. Opin. Clin. Nutr. Metab. Care 10, 129-135. (Pubitemid 46220303)
172. Aksoy, Y., Aksoy, H., Altinkaynak, K., Aydin, H.R., and Ozkan, A. (2006) Sperm fatty acid composition in subfertile men. Prostaglandins Leukot. Essent. Fatty Acids 75, 75-79. (Pubitemid 44287467)
173. Bazan, N.G. (2009) Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins Leukot. Essent. Fatty Acids 81, 205-211.
174. Bouvier, J., Zemski Berry, K.A., Hullin-Matsuda, F., Makino, A., Michaud, S., Geloën, A., Murphy, R.C., Kobayashi, T., Lagarde, M., and Delton-Vandenbroucke, I. (2009) Selective decrease of bis(monoacylglycero) phosphate content in macrophages by high supplementation with docosahexaenoic acid. J. Lipid Res. 50, 243-255.
175. Kagan, V.E., Tyurina, Y.Y., Bayir, H., Chu, C.T., Kapralov, A.A., Vlasova, I.I., Belikova, N.A., Tyurin, V.A., Amoscato, A., Epperly, M., Greenberger, J., Dekosky, S., Shvedova, A.A., and Jiang, J. (2006) The "pro-apoptotic genies" get out of mitochondria: oxidative lipidomics and redox activity of cytochrome c/cardiolipin complexes. Chem. Biol. Interact. 163, 15-28.
176. Broadhurst, C.L., Wang, Y., Crawford, M.A., Cunnane, S.C., Parkington, J.E., and Schmidt, W.F. (2002) Brain-specific lipids from marine, lacustrine, or terrestrial food resources: potential impact on early African Homo sapiens. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 131, 653-673.
177. Cunnane, S.C. and Crawford, M.A. (2003) Survival of the fattest: fat babies were the key to evolution of the large human brain. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 136, 17-26.
178. Larsson, S.C., Kumlin, M., Ingelman-Sundberg, M., and Wolk, A. (2004) Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am. J. Clin. Nutr. 79, 935-945.
179. Lopez-Huertas, E. (2009) Health effects of oleic acid and long chain omega-3 fatty acids (EPA and DHA) enriched milks. A review of intervention studies. Pharmacol. Res. [Epub ahead of print]
180. GISSI-Prevenzione-Investigators (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354, 447-455.
181. Serhan, C.N. and Chiang, N. (2008) Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br. J. Pharmacol. 153, S200-215.
182. Chiang, N. and Serhan, C.N. (2006) Cell-cell interaction in the transcellular biosynthesis of novel omega-3-derived lipid mediators. Methods Mol. Biol. 341, 227-250.
183. Bannenberg, G.L. (2009) Resolvins: current understanding and future potential in the control of inflammation. Curr. Opin. Drug Discov. Dev. 12, 644-658.
184. Serhan, C.N., Clish, C.B., Brannon, J., Colgan, S.P., Chiang, N., and Gronert, K. (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204.
185. Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S., Yang, R., Petasis, N.A., and Serhan, C.N. (2005) Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201, 713-722.
186. Schwab, J.M., Chiang, N., Arita, M., and Serhan, C.N. (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447, 869-874.
187. Haas-Stapleton, E.J., Lu, Y., Hong, S., Arita, M., Favoreto, S., Nigam, S., Serhan, C.N., and Agabian, N. (2007) Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1. PLoS One 2, e1316.
188. Serhan, C.N., Hong, S., Gronert, K., Colgan, S.P., Devchand, P.R., Mirick, G., and Moussignac, R.-L. (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037.
189. Hong, S., Porter, T.F., Lu, Y., Oh, S.F., Pillai, P.S., and Serhan, C.N. (2008) Resolvin E1 metabolome in local inactivation during inflammation- resolution. J. Immunol. 180, 3512-3519.
190. Dona, M., Fredman, G., Schwab, J.M., Chiang, N., Arita, M., Goodarzi, A., Cheng, G., von Andrian, U.H., and Serhan, C.N. (2008) Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 112, 848-855.
191. Arita, M., Oh, S.F., Chonan, T., Hong, S., Elangovan, S., Sun, Y.P., Uddin, J., Petasis, N.A., and Serhan, C.N. (2006) Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J. Biol. Chem. 281, 22847-22854.
192. Jin, Y., Arita, M., Zhang, Q., Saban, D.R., Chauhan, S.K., Chiang, N., Serhan, C.N., and Dana, R. (2009) Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest. Ophthalmol. Vis. Sci. 50(10), 4743-4752.
193. Connor, K.M., SanGiovanni, J.P., Löfqvist, C., Aderman, C.M., Chen, J., Higuchi, A., Hong, S., Pravda, E.A., Majchrzak, S., Carper, D., Hellström, A., Kang, J.X., Chew, E.Y., Salem, N.J., Serhan, C.N., and Smith, L.E. (2007) Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 13, 868-873.
194. Wittamer, V., Franssen, J.D., Vulcano, M., Mirjolet, J.F., Le Poul, E., Migeotte, I., Brezillon, S., Tyldesley, R., Blanpain, C., Detheux, M., Mantovani, A., Sozzani, S., Vassart, G., Parmentier, M., and Communi, D. (2003) Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 198, 977-985.
195. Arita, M., Ohira, T., Sun, Y.-P., Elangovan, S., Chiang, N., and Serhan, C.N. (2007) Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol. 178, 3912-3917.
196. Hasturk, H., Kantarci, A., Goguet-Surmenian, E., Blackwood, A., Andry, C., Serhan, C.N., and Van Dyke, T.E. (2007) Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 179, 7021-7029.
197. Duffield, J.S., Hong, S., Vaidya, V.S., Lu, Y., Fredman, G., Serhan, C.N., and Bonventre, J.V. (2006) Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 177, 5902-5911.
198. Hassan, I.R. and Gronert, K. (2009) Acute changes in dietary omega-3 and omega-6 polyunsaturated fatty acids have a pronounced impact on survival following ischemic renal injury and formation of renoprotective docosahexaenoic acid-derived protectin D1. J. Immunol. 182, 3223-3232.
199. González-Périz, A., Horrillo, R., Ferré, N., Gronert, K., Dong, B., Morán-Salvador, E., Titos, E., Martínez-Clemente, M., López-Parra, M., Arroyo, V., and Clària, J. (2009) Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J. 23, 1946-1957.
200. 4 to promote the resolution of allergic airway inflammation. Nat. Immunol. 9, 873-879.
201. Tjonahen, E., Oh, S.F., Siegelman, J., Elangovan, S., Percarpio, K.B., Hong, S., Arita, M., and Serhan, C.N. (2006) Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 13, 1193-1202. (Pubitemid 44750731)
202. Sun, Y.P., Oh, S.F., Uddin, J., Yang, R., Gotlinger, K., Campbell, E., Colgan, S.P., Petasis, N.A., and Serhan, C.N. (2007) Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J. Biol. Chem. 282, 9323-9334. (Pubitemid 47104612)
203. Hong, S., Gronert, L., Devchand, P.R., Moussignac, R.-L., and Serhan, C.N. (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. J. Biol. Chem. 278, 14677-14687.
204. Merched, A.J., Ko, K., Gotlinger, K.H., Serhan, C.N., and Chan, L. (2008) Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 22, 3595-3606.
205. Spite, M., Norling, L.V., Summers, L., Yang, R., Cooper, D., Petasis, N.A., Flower, R.J., Perretti, M., and Serhan, C.N. (2009) Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461, 1287-1291.
206. Serhan, C.N., Gotlinger, K., Hong, S., Lu, Y., Siegelman, J., Baer, T., Yang, R., Colgan, S.P., and Petasis, N.A. (2006) Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immunol. 176, 1848-1859. (Pubitemid 43134330)
207. Marcheselli, V.L., Hong, S., Lukiw, W.J., Tian, X.H., Gronert, K., Musto, A., Hardy, M., Gimenez, J.M., Chiang, N., Serhan, C.N., and Bazan, N.G. (2003) Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 278, 43807-43817. (Pubitemid 37346009)
208. Mukherjee, P.K., Marcheselli, V.L., Serhan, C.N., and Bazan, N.G. (2004) Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 101, 8491-8496.
209. Bazan, N.G., Ertel, M.K., Knott, E.J., Elison, J.R., Zhou, Y., Bergsma, D.R., Gjörstrup, P., and Gordon, W.C. (2009) Laser-induced choroidal neovascularization is reduced by neuroprotectin D1. In Association for Research in Vision and Ophthalmology Annual Meeting Abstracts. May 3-7, 2009. Fort Lauderdale, FL.
210. Sheets, K.G., Zhou, Y., Elison, J.R., Gjörstrup, P., Gordon, W.C., Bergsma, D.R., and Bazan, N.G. (2009) An analog of resolvin E1 inhibits endothelial cell growth in retina following laser-induced choroidal neovascularization (CNV). In Association for Research in Vision and Ophthalmology Annual Meeting Abstracts. May 3-7, 2009. Fort Lauderdale, FL.
211. Zhou, Y., Gordon, W.C., Elison, J.R., Gjörstrup, P., Bergsma, D.R., and Bazan, N.G. (2009) Topical administration of RX-10045 reduces laser-induced choroidal neovascularization. In Association for Research in Vision and Ophthalmology Annual Meeting Abstracts. May 3-7, 2009. Fort Lauderdale, FL.
212. Bazan, N.G. (2007) Homeostatic regulation of photoreceptor cell integrity: significance of the potent mediator neuroprotectin D1 biosynthesized from docosahexaenoic acid. Invest. Ophtalmol. Vis. Sci. 48, 4866-4881.
213. Serhan, C.N., Yang, R., Martinod, K., Kasuga, K., Pillai, P.S., Porter, T.F., Oh, S.F., and Spite, M. (2009) Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 206, 15-23.
214. Calandria, J.M., Marcheselli, V.L., Mukherjee, P.K., Uddin, J., Winkler, J.W., Petasis, N.A., and Bazan, N.G. (2009) Selective survival rescue in 15-lipoxygenase-1 deficient retinal pigment epithelial cells by the novel docosahexaenoic acid-derived mediator, neuroprotectin D1. J. Biol. Chem. 284(26), 17877-17882.
215. Musiek, E.S., Brooks, J.D., Joo, M., Brunoldi, E., Porta, A., Zanoni, G., Vidari, G., Blackwell, T.S., Montine, T.J., Milne, G.L., McLaughlin, B., and Morrow, J.D. (2008) Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. J. Biol. Chem. 283, 19927-19935.
216. Nakano, J., Anggård, E., and Samuelsson, B. (1969) 15-Hydroxy-prostanoate dehydrogenase. Prostaglandins as substrates and inhibitors. Eur. J. Biochem. 11, 386-389.
217. Camp, R. and Greaves, M.W. (1980) The catabolism of prostaglandins by rat skin. Biochem. J. 186, 153-160.
218. Eling, T.E. and Ally, A.I. (1984) Pulmonary biosynthesis and metabolism of prostaglandins and related substances. Environ. Health Perspect. 55, 159-168. (Pubitemid 14094806)
219. 4 12- hydroxydehydrogenase in inflammation. J. Biol. Chem. 275, 25372-25380.
220. Samuelsson, B., Granström, E., Green, K., Hamberg, M., and Hammarström, S. (1975) Prostaglandins. Annu. Rev. Biochem. 44, 669-695.
221. Chaudhari, A., Anderson, M.W., and Eling, T.E. (1978) Conjugation of 15-keto-prostaglandins by glutathione S-transferases. Biochim. Biophys. Acta 531, 56-64.
222. 4 by human neutrophil microsomes. FEBS Lett. 315, 205-210.
223. Diczfalusy, U. (1994) Beta-oxidation of eicosanoids. Prog. Lipid Res. 33, 403-428.
224. Parkinson, J.F. (2006) Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflamm. Allergy Drug Targets 5, 91-106.
225. Bannenberg, G.L. (2007) Anti-inflammatory actions of lipoxins. Exp. Opin. Ther. Patents 17, 591-605.
226. Stürzebecher, S., Haberey, M., Müller, B., Schillinger, E., Schröder, G., Skuballa, W., Stock, G., Vorbrüggen, H., and Witt, W. (1986) Pharmacological profile of a novel carbacyclin derivative with high metabolic stability and oral activity in the rat. Prostaglandins 31, 95-109.
227. Kasuga, K., Yang, R., Porter, T.F., Agrawal, N., Petasis, N.A., Irimia, D., Toner, M., and Serhan, C.N. (2008) Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J. Immunol. 181, 8677-8687.
228. Grimminger, F., Grimm, H., Führer, D., Papavassilis, C., Lindemann, G., Blecher, C., Mayer, K., Tabesch, F., Krämer, H.J., Stevens, J., and Seeger, W. (1996) Omega-3 lipid infusion in a heart allotransplant model. Shift in fatty acid and lipid mediator profiles and prolongation of transplant survival. Circulation 93, 365-371. (Pubitemid 26031497)
229. Driscoll, D.F. (2006) Lipid injectable emulsions: 2006. Nutr. Clin. Pract. 21, 381-386.
230. Lukiw, W.J., Cui, J.G., Marcheselli, V.L., Bodker, M., Botkjaer, A., Gotlinger, K., Serhan, C.N., and Bazan, N.G. (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 115, 2774-2783. (Pubitemid 41434404)
231. Belayev, L., Marcheselli, V.L., Khoutorova, L., Rodriguez de Turco, E.B., Busto, R., Ginsberg, M.D., and Bazan, N.G. (2005) Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke 36, 118-123. (Pubitemid 40054186)
232. Poulsen, R.C., Gotlinger, K.H., Serhan, C.N., and Kruger, M.C. (2008) Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega-3 intake. Am. J. Hematol. 83, 437-445.
233. Mayer, K., Kiessling, A., Ott, J., Schaefer, M.B., Hecker, M., Henneke, I., Schulz, R., Günther, A., Wang, J., Wu, L., Roth, J., Seeger, W., and J.X., K. (2009) Acute lung injury is reduced in fat-1 mice endogenously synthesizing n-3 fatty acids. Am. J. Respir. Crit. Care Med. 179, 474-483.
234. Mernitz, H., Lian, F., Smith, D.E., Meydani, S.N., and Wang, X.D. (2009) Fish oil supplementation inhibits NNK-induced lung carcinogenesis in the A/J mouse. Nutr. Cancer 61, 663-669.
235. González-Périz, A., Planagumà, A., Gronert, K., Miquel, R., López-Parra, M., Titos, E., Horrillo, R., Ferré, N., Deulofeu, R., Arroyo, V., Rodés, J., and Clària, J. (2006) Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J. 20, 2537-2539.
236. Lindgren, J.A., Stenke, L., Mansour, M., Edenius, C., Laurén, L., Näsman-Glaser, B., Ericsson, I., and Reizenstein, P. (1993) Formation and effects of leukotrienes and lipoxins in human bone marrow. J. Lipid Mediat. 6, 313-320.
237. 4 are regulatory signals for neural stem cell proliferation and differentiation. FASEB J. 20, 1785-1792.
238. Scott, B.L. and Bazan, N.G. (1989) Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. Proc. Natl. Acad. Sci. U. S. A. 86, 2903-2907.
239. Pontes-Arruda, A., Demichele, S., Seth, A., and Singer, P. (2008) The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data. JPEN J. Parenter. Enteral Nutr. 32, 596-605.
240. Rühl, R., Koch, C., Marosvölgyi, T., Mihály, J., Schweigert, F.J., Worm, M., and Decsi, T. (2008) Fatty acid composition of serum lipid classes in mice following allergic sensitisation with or without dietary docosahexaenoic acid-enriched fish oil substitution. Br. J. Nutr. 99, 1239-1246.
241. 2-isoprostanes but enhances inflammatory cytokine response in a mouse model of ovalbumin-induced allergic lung inflammation. Free Radic. Biol. Med. 47, 622-628.
242. Dangi, B., Obeng, M., Nauroth, J.M., Chung, G., Bailey-Hall, E., Hallenbeck, T., and Arterburn, L.M. (2009) Metabolism and biological production of resolvins derived from docosapentaenoic acid (DPAn-6). Biochem. Pharmacol. 79, 251-260.
243. Dangi, B., Obeng, M., Nauroth, J.M., Teymourlouei, M., Needham, M., Raman, K., and Arterburn, L.M. (2009) Biogenic synthesis, purification, and chemical characterization of anti-inflammatory resolvins derived from docosapentaenoic acid (DPAn-6). J. Biol. Chem. 284, 14744-14759.
244. Serhan, C.N., Hamberg, M., Ramstedt, U., and Samuelsson, B. (1986) Lipoxins: stereochemistry, biosynthesis and biological activities. Adv. Prostaglandin Thromboxane Leukot. Res. 16, 83-97.
245. Serhan, C.N., Nicolaou, K.C., Webber, S.E., Veale, C.A., Dahlen, S.E., Puustinen, T.J., and Samuelsson, B. (1986) Lipoxin A. Stereochemistry and biosynthesis. J. Biol. Chem. 261, 16340-16345.
246. 4 analogs with enhanced stability and potent anti-inflammatory properties. Bioorg. Med. Chem. Lett. 18, 1382-1387.
247. 4: structure-function relationships. Biochem. Biophys. Res. Commun. 180, 1416-14121.
248. Bannenberg, G., Moussignac, R.L., Gronert, K., Devchand, P.R., Schmidt, B.A., Guilford, W.J., Bauman, J.G., Subramanyam, B., Perez, H.D., Parkinson, J.F., and Serhan, C.N. (2004) Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br. J. Pharmacol. 143, 43-52. (Pubitemid 39280023)
249. 4 analogs. Prostaglandins Leukot. Essent. Fatty Acids 81, 357-366.
250. 4 analogs. Prostaglandins Leukot. Essent. Fatty Acids 73, 245-250.
251. Tai, H.H., Ensor, C.M., Tong, M., Zhou, H., and Yan, F. (2002) Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 68-69, 483-493.
252. Kunkel, S.L., Ogawa, H., Conran, P.B., Ward, P.A., and Zurier, R.B. (1981) Suppression of acute and chronic inflammation by orally administered prostaglandins. Arthritis Rheum. 24, 1151-1158. (Pubitemid 11057342)
253. Clish, C.B., O'Brien, J.A., Gronert, K., Stahl, G.L., Petasis, N.A., and Serhan, C.N. (1999) Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. U. S. A. 96, 8247-8252. (Pubitemid 29328440)
254. Robert, A., Bundy, G.L., Field, S.O., Nezamis, J.E., Davis, J.P., Hanchar, A.J., Lancaster, C., and Ruwart, M.J. (1985) Prevention of cecitis in hamsters by certain prostaglandins. Prostaglandins 29, 961-980. (Pubitemid 15050445)
255. Kitsis, E.A., Weissmann, G., and Abramson, S.B. (1991) The prostaglandin paradox: additive inhibition of neutrophil function by aspirin-like drugs and the prostaglandin E1 analog misoprostol. J. Rheumatol. 18, 1461-1465.
256. Stjernschantz, J. (2004) Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment. Exp. Eye Res. 78, 759-766. (Pubitemid 38252952)
257. Russo, A., Riva, I., Pizzolante, T., Noto, F., and Quaranta, L. (2008) Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clin. Ophthalmol. 2, 897-905.
258. Schottelius, A.J., Giesen, C., Asadullah, K., Fierro, I.M., Colgan, S.P., Bauman, J., Guilford, W., Perez, H.D., and Parkinson, J.F. (2002) An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J. Immunol. 169, 7063-7070. (Pubitemid 36899294)
259. Ahluwalia, A. and Perretti, M. (1994) Anti-inflammatory effect of prostanoids in mouse and rat skin: evidence for a role of EP3-receptors. J. Pharmacol. Exp. Ther. 268, 1526-1531. (Pubitemid 24100375)
260. 4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol. 168, 5260-5267.
261. 2 methyl analogues in the rat pulmonary circulation. Br. J. Pharmacol. 62, 275-280.
262. 1 polymeric prodrug and its potential for preventing carbon tetrachloride-induced fulminant hepatitis in mice. J. Pharmacol. Exp. Ther. 290, 1242-1249.
263. 4 in endotoxin-induced uveitis. Mol. Pharmacol. 74, 154-161.
264. Gronert, K., Martinsson-Niskanen, T., Ravasi, S., Chiang, N., and Serhan, C.N. (2001) Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am. J. Pathol. 158, 3-9.
265. Kolaczkowska, E., Shahzidi, S., Seljelid, R., van Rooijen, N., and Plytycz, B. (2002) Early vascular permeability in murine experimental peritonitis is comediated by residential peritoneal macrophages and mast cells: crucial involvement of macrophage-derived cysteinyl-leukotrienes. Inflammation 26, 61-70.
266. Montuschi, P., Sala, A., Dahlén, S.E., and Folco, G. (2007) Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov. Today 12, 404-412.
267. 4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc. Natl. Acad. Sci. U. S. A. 102, 17501-17506.
268. Ahluwalia, N., Lin, A.Y., Tager, A.M., Pruitt, I.E., Anderson, T.J., Kristo, F., Shen, D., Cruz, A.R., Aikawa, M., Luster, A.D., and Gerszten, R.E. (2007) Inhibited aortic aneurysm formation in BLT1-deficient mice. J. Immunol. 179, 691-697.
269. 4 receptor 1 in allergen-induced airway hyper-responsiveness. Am. J. Resp. Crit. Care Med. 172, 161-167.
270. 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J. Clin. Invest. 104, 309-316.
271. 4. Agents Actions 32, 85-87.
272. Cash, J.L., Hart, R., Russ, A., Dixon, J.P., Colledge, W.H., Doran, J., Hendrick, A.G., Carlton, M.B., and Greaves, D.R. (2008) Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J. Exp. Med. 205, 767-775.
273. Shimamura, K., Matsuda, M., Miyamoto, Y., Yoshimoto, R., Seo, T., and Tokita, S. (2009) Identification of a stable chemerin analog with potent activity toward ChemR23. Peptides 30, 1529-1538.
274. Bürli, R.W., Xu, H., Zou, X., Muller, K., Golden, J., Frohn, M., Adlam, M., Plant, M.H., Wong, M., McElvain, M., Regal, K., Viswanadhan, V.N., Tagari, P., and Hungate, R. (2006) Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg. Med. Chem. Lett. 16, 3713-3718.
275. 2 and 2-cyclopenten-1-one: role of the heat shock response. Mol. Pharmacol. 64, 85-93.
276. 2 attenuates development of cyclophosphamide-induced cystitis in rats. Urology 76, 435-439.
277. 2: role of glutathione. FEBS Lett. 579, 5803-5808.
278. Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., and Santoro, M.G. (2000) Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IêB kinase. Nature 403, 103-108.
279. Bickley, J.F., Ciucci, A., Evans, P., Roberts, S.M., Ross, N., and Santoro, G. (2004) Reactions of some cyclopentenones with selected cysteine derivatives and biological activities of the product thioethers. Bioorg. Med. Chem. 12, 3221-3227.
280. Homem de Bittencourt, P.J., Lagranha, D.J., Maslinkiewicz, A., Senna, S.M., Tavares, A.M., Baldissera, L.P., Janner, D.R., Peralta, J.S., Bock, P.M., Gutierrez, L.L., Scola, G., Heck, T.G., Krause, M.S., Cruz, L.A., Abdalla, D.S., Lagranha, C.J., Lima, T., and Curi, R. (2007) LipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions. Atherosclerosis 139, 245-258.
281. Rodríguez, A.M., Enriz, R.D., Santagata, L.N., Jáuregui, E.A., Pestchanker, M.J., and Giordano, O.S. (1997) Structure-cytoprotective activity relationship of simple molecules containing an α,β- unsaturated carbonyl system. J. Med. Chem. 40, 1827-1834.
282. Ciucci, A., Gianferretti, P., Piva, R., Guyot, T., Snape, T.J., Roberts, S.M., and Santoro, M.G. (2006) Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factor-kappaB pathway. Mol. Pharmacol. 70, 1812-1821.
283. Satoh, T., Furuta, K., Tomokiyo, K., Nakatsuka, D., Tanikawa, M., Nakanishi, M., Miura, M., Tanaka, S., Koike, T., Hatanaka, H., Ikuta, K., Suzuki, M., and Watanabe, Y. (2000) Facilitatory roles of novel compounds designed from cyclopentenone prostaglandins on neurite outgrowth-promoting activities of nerve growth factor. J. Neurochem. 75, 1092-1102.
284. Verbitski, S.M., Mullally, J.E., Fitzpatrick, F.A., and Ireland, C.M. (2004) Punaglandins, chlorinated prostaglandins, function as potent Michael receptors to inhibit ubiquitin isopeptidase activity. J. Med. Chem. 47, 2062-2070.
285. Fukunaga, K., Kohli, P., Bonnans, C., Fredenburgh, L.E., and Levy, B.D. (2005) Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J. Immunol. 174, 5033-5039.
286. Colville-Nash, P.R. and Gilroy, D.W. (2001) Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation. BioDrugs 15, 1-9.
287. Blaho, V.A., Mitchell, W.J., and Brown, C.R. (2008) Arthritis develops but fails to resolve during inhibition of cyclooxygenase 2 in a murine model of Lyme disease. Arthritis Rheum. 58, 1485-1495.
288. Zurier, R.B., Sun, Y.P., George, K.L., Stebulis, J.A., Rossetti, R.G., Skulas, A., Judge, E., and Serhan, C.N. (2009) Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. FASEB J. 23, 1503-1509.
289. Stebulis, J.A., Johnson, D.R., Rossetti, R.G., Burstein, S.H., and Zurier, R.B. (2008) Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life Sci. 83, 666-670.
290. Beck-Speier, I., Oswald, B., Maier, K.L., Karg, E., and Ramseger, R. (2009) Oxymetazoline inhibits and resolves inflammatory reactions in human neutrophils. J. Pharmacol. Sci. 110, 276-284.
291. Molina-Molina, M., Serrano-Mollar, A., Bulbena, O., Fernandez-Zabalegui, L., Closa, D., Marin-Arguedas, A., Torrego, A., Mullol, J., Picado, C., and Xaubet, A. (2006) Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis. Thorax 61, 604-610.
292. 4 and heme-oxygenase in counter-regulating inflammation during corneal wound healing. FASEB J. 21, 2257-2266.
293. 4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1. Anesth. Analg. 104, 369-377.
294. 4 act in concert to regulate neutrophil trafficking: additive actions of two new endogenous anti-inflammatory mediators. J. Hematother. Stem Cell Res. 10, 75-79.
295. 4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J. Exp. Med. 200, 69-78.
296. Baker, P.R., Schopfer, F.J., O'Donnell, V.B., and Freeman, B.A. (2009) Convergence of nitric oxide and lipid signaling: anti-inflammatory nitro-fatty acids. Free Radic. Biol. Med. 46, 989-1003.
297. Khoo, N.K., Rudolph, V., Cole, M.P., Golin-Bisello, F., Schopfer, F.J., Woodcock, S.R., Batthyany, C., and Freeman, B.A. (2010) Activation of vascular endothelial nitric oxide synthase and heme oxygenase-1 expression by electrophilic nitro-fatty acids. Free Radic. Biol. Med. 48(2), 230-239.
298. 4 receptor. Nat. Med. 8, 1296-1302.
299. 2 biosynthesis. J. Clin. Invest. 119, 1477-1488.
300. Hennebert, O., Pelissier, M.A., Le Mee, S., Wülfert, E., and Morfin, R. (2008) Anti-inflammatory effects and changes in prostaglandin patterns induced by 7.-hydroxy-epiandrosterone in rats with colitis. J. Steroid Biochem. Mol. Biol. 110, 255-262.
301. Saw, C.L., Huang, Y., and Kong, A.N. (2010) Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem. Pharmacol. 79, 421-430.
302. 4 receptor expression are decreased in severe asthma. Am. J. Respir. Crit. Care Med. 178, 574-582.
303. Karp, C.L., Flick, L.M., Park, K.W., Softic, S., Greer, T.M., Keledjian, R., Yang, R., Uddin, J., Guggino, W.B., Atabani, S.F., Belkaid, Y., Xu, Y., Whitsett, J.A., Accurso, F.J., Wills-Karp, M., and Petasis, N.A. (2004) Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5, 388-392.
304. Kowal-Bielecka, O., Kowal, K., Distler, O., Rojewska, J., Bodzenta-Lukaszyk, A., Michel, B.A., Gay, R.E., Gay, S., and Sierakowski, S. (2005) Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum. 52, 3783-3791.
305. Starosta, V., Ratjen, F., Rietschel, E., Paul, K., and Griese, M. (2006) Anti-inflammatory cytokines in cystic fibrosis lung disease. Eur. Respir. J. 28, 581-587.
306. Hasturk, H., Kantarci, A., Ohira, T., Arita, M., Ebrahimi, N., Chiang, N., Petasis, N.A., Levy, B.D., Serhan, C.N., and Van Dyke, T.E. (2006) RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. FASEB J. 20, 401-403.
307. Brown, J.R., Goldblatt, D., Buddle, J., Morton, L., and Thrasher, A.J. (2003) Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J. Leukoc. Biol. 73, 591-599.
308. Maekawa, A., Austen, K.F., and Kanaoka, Y. (2002) Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J. Biol. Chem. 277, 20820-20824.
309. Beller, T.C., Friend, D.S., Maekawa, A., Lam, B.K., Austen, K.F., and Kanaoka, Y. (2004) Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc. Natl. Acad. Sci. U. S. A. 101, 3047-3052.
310. 4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc. Natl. Acad. Sci. U. S. A. 105, 16695-16700.
311. Wallace, J.L. (2008) Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol. Rev. 88, 1547-1565.
312. Canny, G., Levy, O., Furuta, G.T., Narravula-Alipati, S., Sisson, R.B., Serhan, C.N., and Colgan, S.P. (2002) Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc. Natl. Acad. Sci. U. S. A. 99, 3902-3907.
313. Barnes, P.J. and Adcock, I.M. (2009) Glucocorticoid resistance in inflammatory diseases. Lancet 373, 1905-1917.
314. Sanak, M., Levy, B.D., Clish, C.B., Chiang, N., Gronert, K., Mastalerz, L., Serhan, C.N., and Szczeklik, A. (2000) Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur. Respir. J. 16, 44-49.
315. Gronert, K., Clish, C.B., Romano, M., and Serhan, C.N. (1999) Transcellular regulation of eicosanoid biosynthesis. Methods Mol. Biol. 120, 119-144.